GRI Bio近日宣布,其针对特发性肺纤维化(IPF)开展的二期a期临床研究获得额外积极数据。这些新发现进一步强化了候选药物GRI-0621的临床概念验证,为后续开发提供有力支撑。
GRI Bio近日宣布,其针对特发性肺纤维化(IPF)开展的二期a期临床研究获得额外积极数据。这些新发现进一步强化了候选药物GRI-0621的临床概念验证,为后续开发提供有力支撑。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.